Literature DB >> 24593257

Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects.

Silvia Spinozzi1, Carolina Colliva, Cecilia Camborata, Marinella Roberti, Cristina Ianni, Flavia Neri, Claudio Calvarese, Andrea Lisotti, Giuseppe Mazzella, Aldo Roda.   

Abstract

Berberine (1) is an alkaloid used widely in the treatment of several diseases. However, its physicochemical properties, pharmacokinetics, and metabolism remain unclear, and conflicting data have been reported. In this study, the main physicochemical properties of 1 and its metabolites were evaluated, including lipophilicity, solubility, pKa, and albumin binding. A sensitive HPLC-ESIMS/MS method was developed and validated to identify 1 and its main metabolites in human plasma. This method was used to quantify their levels in the plasma of healthy volunteers and hypercholesterolemic patients following a single dose and chronic administration, respectively. In both cases, berberrubine (2) was found to be the main metabolite. Surprisingly, 2 is more lipophilic than 1, which suggests that this compound tautomerizes to a highly conjugated, electroneutral quinoid structure. This was confirmed by NMR studies. These results indicate that the higher plasma concentration of 2 was a consequence of a more efficient intestinal absorption, suggesting that berberrubine is potentially more pharmacologically active than berberine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24593257     DOI: 10.1021/np400607k

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  31 in total

1.  In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.

Authors:  Na Yang; Run-Bin Sun; Xing-Long Chen; Le Zhen; Chun Ge; Yu-Qing Zhao; Jun He; Jian-Liang Geng; Jia-Hua Guo; Xiao-Yi Yu; Fei Fei; Si-Qi Feng; Xuan-Xuan Zhu; Hong-Bo Wang; Feng-Hua Fu; Ji-Ye Aa; Guang-Ji Wang
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

2.  Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells.

Authors:  Wenguang Chang; Ming Zhang; Li Chen; Grant M Hatch
Journal:  Lipids       Date:  2017-09-23       Impact factor: 1.880

3.  Inhibition of Bacteroidetes and Firmicutes by select phytochemicals.

Authors:  Jourdan E Lakes; Christopher I Richards; Michael D Flythe
Journal:  Anaerobe       Date:  2019-12-24       Impact factor: 3.331

Review 4.  Metformin and metabolic diseases: a focus on hepatic aspects.

Authors:  Juan Zheng; Shih-Lung Woo; Xiang Hu; Rachel Botchlett; Lulu Chen; Yuqing Huo; Chaodong Wu
Journal:  Front Med       Date:  2015-02-12       Impact factor: 4.592

5.  Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail.

Authors:  James T Nguyen; Dan-Dan Tian; Rakshit S Tanna; Deena L Hadi; Sumit Bansal; Justina C Calamia; Christopher M Arian; Laura M Shireman; Bálint Molnár; Miklós Horváth; Joshua J Kellogg; Matthew E Layton; John R White; Nadja B Cech; Richard D Boyce; Jashvant D Unadkat; Kenneth E Thummel; Mary F Paine
Journal:  Clin Pharmacol Ther       Date:  2020-12-23       Impact factor: 6.875

6.  Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2022-01-20       Impact factor: 2.953

7.  Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro.

Authors:  Keshav R Paudel; Meenu Mehta; Geena Hew Suet Yin; Lee Li Yen; Vamshikrishna Malyla; Vyoma K Patel; Jithendra Panneerselvam; Thiagarajan Madheswaran; Ronan MacLoughlin; Niraj Kumar Jha; Piyush Kumar Gupta; Sachin Kumar Singh; Gaurav Gupta; Pradeep Kumar; Brian G Oliver; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-16       Impact factor: 5.190

8.  Effect of topical berberine in murine cutaneous leishmaniasis lesions.

Authors:  Alba Calvo; Esther Moreno; Irati Aldalur; Carmen Sanmartín; Esther Larrea; Elena González-Peñas; Juan Manuel Irache; Socorro Espuelas
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 9.  Potential benefits of berberine in the management of perimenopausal syndrome.

Authors:  Cristiana Caliceti; Paola Rizzo; Arrigo Francesco Giuseppe Cicero
Journal:  Oxid Med Cell Longev       Date:  2015-02-17       Impact factor: 6.543

10.  Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe-/- mice with hyperhomocysteinemia.

Authors:  Hongjun Li; Chengyan He; Jingying Wang; Xiaoou Li; Zhaowei Yang; Xiaoying Sun; Ling Fang; Ning Liu
Journal:  J Diabetes Investig       Date:  2016-04-15       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.